Share

About Us

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.

Contacts

  • Ulf Hannelius

    CEO


    Kungsgatan 29, SE-111 56 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com
  • Subscribe

    Media